[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344449-105":59,"doc-detail-344449-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","parylation-centric-crosstalk-orchestrating-immune-evasion-and-multidrug-resistance-in-ovarian-cancer","PARylation-centric crosstalk - orchestrating immune evasion and multidrug resistance in ovarian cancer","","This review synthesizes evidence on how PARylation and broader post-translational modification (PTM) networks shape ovarian cancer pathogenesis. It highlights PARylation roles in DNA repair, immune evasion, and therapeutic resistance, including interactions with ubiquitination, phosphorylation, acetylation, methylation, and glycosylation. Mechanistic coverage includes PARP1/2 control of cGAS/STING signaling, effects on immune cells, and resistance involving histone methylation and PARP1 stabilization. The article evaluates combinatorial treatments using PARP inhibitors with DNA-damage, immune-checkpoint, and metabolic strategies, and reviews preclinical delivery, PROTACs, and ferroptosis approaches while discussing translational barriers and biomarker needs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parylation-centric-crosstalk-orchestrating-immune-evasion-and-multidrug-resistance-in-ovarian-cancer/344449/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parylation-centric-crosstalk-orchestrating-immune-evasion-and-multidrug-resistance-in-ovarian-cancer/344449.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the central focus of this review on ovarian cancer?","Question",{"text":112,"@type":113},"The review focuses on PARylation-centric crosstalk and how interactions between PARylation and other PTM networks orchestrate immune evasion and multidrug resistance in ovarian cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which immune-related pathways are discussed in connection with PARylation?",{"text":117,"@type":113},"The review discusses PARP1/2-mediated regulation of cGAS/STING signaling and how PTMs influence immune checkpoint activity such as PD-L1, affecting the tumor immune microenvironment.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review approach treatment strategies involving PARP inhibitors?",{"text":121,"@type":113},"It evaluates combinatorial approaches pairing PARP inhibitors with ATR/CHK1 inhibition, immune checkpoint blockade, or metabolic targeting, and it also surveys emerging combinations and preclinical modalities such as nanoparticle delivery and PROTACs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344449,1790802959,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","TYPE Review  \nPUBLISHED 01 May 2026  \nDOI 10.3389/fimmu.2026.1772562  \nOPEN ACCESS  \nEDITED BY  \nHeng Zhang,  \nNankai University, China  \nREVIEWED BY  \nDeepa Bisht,  \nJawaharlal Nehru University, India Wajid Ahmad,  \nSant Gadge Baba Amravati University, India  \n*CORRESPONDENCE  \nWeihua Tong  \n [tongwh@jlu.edu.cn](tongwh@jlu.edu.cn)[ ](tongwh@jlu.edu.cn)Songling Zhang  \n [slzhang@jlu.edu.cn](slzhang@jlu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 21 December 2025  \nREVISED 24 March 2026  \nACCEPTED 07 April 2026  \nPUBLISHED 01 May 2026  \nCITATION  \nHou L, Zhang M, Tong W and Zhang S (2026) PARylation-centric crosstalk:  \norchestrating immune evasion and multidrug resistance in ovarian cancer. Front. Immunol. 17:1772562 .  \ndoi: 10.3389/fimmu.2026.1772562  \nCOPYRIGHT  \n© 2026 Hou, Zhang, Tong and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPARylation-centric crosstalk: orchestrating immune evasion and multidrug resistance in ovarian cancer  \nLin Hou 1,2†, Mengwen Zhang 1,2†, Weihua Tong 1* and Songling Zhang 1,2*  \n1 Department of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China, 2Jilin Provincial Key Laboratory of Women ’s Reproductive Health, Changchun, China  \nPost-translational modiﬁcations (PTMs) play pivotal roles in ovarian cancer pathogenesis, with poly(ADP-ribosyl)ation (PARylation) serving as a key regulator of DNA repair, immune evasion, and therapeutic resistance. Beyond PARylation, diverse PTM networks—including ubiquitination, phosphorylation, acetylation, methylation, and glycosylation—orchestrate signaling cascades that shape tumor progression and immune recognition. Aberrant glycosylation of MUC16 (CA125) and immune checkpoints such as PD-L1 exempliﬁes how PTMs modulate the tumor immune microenvironment. This review synthesizes current evidence on the interplay between PARylation and other PTM networks in ovarian cancer, with emphasis on their roles in DNA repair, immune modulation, and drug resistance. We discuss PARP1/2-mediated regulation of cGAS/STING signaling and immune cell activity, alongside resistance mechanisms involving EHMT1/2-associated histone methylation, SPINDOC-enhanced PARylation, and ubiquitin-dependent PARP1 stabilization. Therapeutically, we evaluate combinatorial approaches pairing PARP inhibitors with ATR/CHK1 inhibition, immune checkpoint blockade, or metabolic targeting. Emerging strategies combining PARP inhibitors with PRMT, UBA1, WEE1, or MEK inhibitors are examined, alongside recent clinical trials including the GINECO study of bevacizumab, olaparib, and durvalumab. Mechanistic insights into PARP inhibitor-induced T cell DNA damage and strategies to preserve lymphocyte function are also discussed. Preclinical approaches involving nanoparticle delivery, PROTACs, and ferroptosis induction are reviewed for their potential to disrupt PARylation networks. Despite these advances, clinical translation faces substantial challenges, including patient heterogeneity, overlapping toxicities, adaptive resistance through PTM network rewiring, and the need for predictive biomarkers beyond BRCA mutation status. Current obstacles in resolving spatiotemporal PTM dynamics and cancer stem cell-speciﬁc vulnerabilities are outlined. This work aims to inform future research on targeting PARylationassociated PTM pathways to overcome ovarian cancer’s evolvable resistance.  \nKEYWORDS  \ndrug resistance, immunity of cancer, ovarian cancer, PARylation, post-translational modiﬁcation  \nFrontiers in Immunology 01 [frontiersin.org](frontiersi","cbCaiaXKAGLEuvtK","https://ap.wps.com/l/cbCaiaXKAGLEuvtK","pdf",1448998,17,"English","# Introduction\n## PARylation and PTMs in tumor development and resistance\n## PARylation-regulated immune evasion in ovarian cancer\n## Therapeutic strategies targeting PARylation-associated networks","[{\"question\":\"What is the central focus of this review on ovarian cancer?\",\"answer\":\"The review focuses on PARylation-centric crosstalk and how interactions between PARylation and other PTM networks orchestrate immune evasion and multidrug resistance in ovarian cancer.\"},{\"question\":\"Which immune-related pathways are discussed in connection with PARylation?\",\"answer\":\"The review discusses PARP1/2-mediated regulation of cGAS/STING signaling and how PTMs influence immune checkpoint activity such as PD-L1, affecting the tumor immune microenvironment.\"},{\"question\":\"How does the review approach treatment strategies involving PARP inhibitors?\",\"answer\":\"It evaluates combinatorial approaches pairing PARP inhibitors with ATR/CHK1 inhibition, immune checkpoint blockade, or metabolic targeting, and it also surveys emerging combinations and preclinical modalities such as nanoparticle delivery and PROTACs.\"}]","PARylation-centric crosstalk - orchestrating immune evasion and multidrug resistance in ovarian cancer | PDF",1790053814,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/756e9c1fed5c10c7f51a07c86ba9d5e0.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bf93d12039433924305b1ff06a64824.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97a258308c2c988ca68668c4eb5ec480.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/734ca70b8cd32d135ce56f970990516b.webp",980,1385]